Chemotherapeutic targeting of myeloid-derived suppressor cells
Darya Alizadeh1, Emmanuel Katsanis2, Nicolas Larmonier2
1Department of Pediatrics; Steele Children's Research Center; the University of Arizona Cancer Center; Tucson, AZ USA ; Cancer Biology Graduate Program; University of Arizona; Tucson, AZ USA.
Abstract:
Myeloid-derived suppressor cells (MDSCs), which expand in cancer-bearing hosts, contribute to the escape of malignant cells from immune destruction and impair the efficacy of immunotherapeutic interventions. We have recently demonstrated that the conventional chemotherapeutic agent doxorubicin selectively eliminates MDSCs, hence promoting the activity of immune effector cells and improving the therapeutic profile of adoptively transferred helper T lymphocytes.
More Related Videos
08:41Functional Characterization of Regulatory Macrophages That Inhibit Graft-reactive Immunity
Published on: June 7, 2017
09:57Real Time Detection of In Vitro Tumor Cell Apoptosis Induced by CD8+ T Cells to Study Immune Suppressive Functions of Tumor-infiltrating Myeloid Cells
Published on: January 29, 2019
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Differentiation of Common Myeloid Progenitor Cells
